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BACKGROUND AND AIMS: DNA ploidy abnormalities (aneuploidy/tetraploidy) measured by flow cytometry (FC) are strong predictors of
future cancer development in untreated Barrett’s oesophagus, independent of histology grade. Image cytometric DNA analysis
(ICDA) is an optical technique allowing visualisation of abnormal nuclei that may be undertaken on archival tissue. Our aim was to
determine the accuracy of ICDA vs FC, and evaluate DNA ploidy as a prognostic biomarker after histologically successful treatment
with photodynamic therapy (PDT).
METHODS: Nuclei were extracted from 40mm sections of paraffin-embedded biopsies and processed for ICDA at UCL and FC at UW
using standardised protocols. Subsequently, DNA ploidy was evaluated by ICDA on a cohort of 30 patients clear of dysplasia 1 year
after aminolaevulinic acid PDT for high-grade dysplasia (HGD). The results were correlated with long-term outcome.
RESULTS: In the comparative study, 93% (41 out of 44) of cases were classified identically. Errors occurred in the near-diploid region by
ICDA and the tetraploid region by FC. In the cohort study, there were 13 cases of late relapse (7 cancer, 6 HGD) and 17 patients
who remained free of dysplasia after a mean follow-up of 44 months. Aneuploidy post-PDT was highly predictive for recurrent HGD
or cancer with a hazard ratio of 8.2 (1.8–37.8) (log-rank P¼0.001).
CONCLUSIONS: ICDA is accurate for the detection of DNA ploidy abnormalities when compared with FC. After histologically
successful PDT, patients with residual aneuploidy are significantly more likely to develop HGD or cancer than those who become
diploid. DNA ploidy by ICDA is a valuable prognostic biomarker after ablative therapy.
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The incidence of oesophageal adenocarcinoma is rising rapidly in
the developed world. Barrett’s oesophagus (BE) is a precursor
lesion that confers an increased risk of oesophageal adenocarci-
noma, with incidence rates of 0.4–2% per annum (Cameron et al,
1985; Robertson et al, 1988; Hameeteman et al, 1989; Williamson
et al, 1991). Progression seems to occur through a metaplasia–
dysplasia–carcinoma sequence (Weston et al, 1999; Montgomery
et al, 2001). High-grade dysplasia (HGD) confers a high probability
of cancer, with rates varying between 31 and 59% over 5 years
(Reid et al, 2000a; Buttar et al, 2001; Overholt et al, 2007). In recent
years, there has been a paradigm shift in the treatment of HGD in
BE from oesophagectomy to endoscopic therapy, with focal
ablation of nodular disease (endoscopic mucosal resection
(EMR)) and field ablation of residual flat dysplasia (photodynamic
therapy (PDT), argon plasma coagulation, radiofrequency ablation
and cryotherapy). The effectiveness of these approaches in
eradicating HGD and reducing the risk of progression to cancer
has been shown in randomised controlled trials (Overholt et al,
2007; Shaheen et al, 2009).
Although complete ablation of a Barrett’s segment is the ideal
response to treatment, complete reversal of HGD at 1 year is
currently used as a marker of treatment success post-ablative
therapy (Overholt et al, 2007; Shaheen et al, 2009). Nevertheless, in
one series, late relapse beyond 2 years occurred in up to 23% of
patients (Overholt et al, 2007). It is, therefore, necessary to
perform regular surveillance endoscopy and biopsy, which is both
unpleasant for patients and expensive. This has generated interest
in the potential usage of biomarkers to predict success of
treatment.
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sDNA ploidy abnormalities (aneuploidy/tetraploidy) measured
by flow cytometry (FC) have been shown to be an independent risk
factor for the development of cancer in untreated BE, independent
of histology grade (Reid et al, 2000b; Rabinovitch et al, 2001). If a
patient had both HGD and aneuploidy or DNA tetraploidy, the risk
of developing cancer within 5 years was 66%, compared with 42%
with HGD alone and 28% with DNA ploidy abnormalities alone.
None of the 215 patients without HGD who were diploid (no
cytometric abnormality) developed cancer during 5 years of
follow-up (Reid et al, 2000b).
Image cytometric DNA analysis (ICDA) is a comparable
technique to FC for the detection of DNA ploidy abnormalities;
ICDA is advantageous as set-up cost is low, only a small number
of nuclei are required, it is more sensitive for the analysis of
tetraploid cell populations (Russack, 1994), and it is routinely
performed on formalin-fixed paraffin-embedded (FFPE) samples,
which allows analysis of archival material, valuable when planning
longitudinal studies on disease progression.
The aim of this study is to evaluate the accuracy of ICDA vs FC,
and to determine whether residual DNA ploidy abnormalities after
successful treatment with PDT predict late relapse to HGD or
cancer.
MATERIALS AND METHODS
Samples for comparative study of image cytometry and FC
A total of 35 patients from the UCLH BE database who underwent
either oesophagectomy or EMR between 2005 and 2008 were
randomly selected. A total of 48 FFPE blocks were retrieved
and chosen for transportation to UW (16 EMR specimens and
32 blocks from oesophagectomy specimens). The EMR blocks
were either low-grade dysplasia, HGD, carcinoma in situ or intra-
mucosal cancer. Of the oesophagectomy specimens, 25 had
invasive adenocarcinoma. A further seven blocks of cancer-free
margins (six squamous oesophagus, one BE) were used as controls.
Image cytometry
Preparation of the monolayer Two 40mm sections were cut from
FFPE tissue and transported at room temperature to UW, Seattle.
The sample was then processed by a variation of the technique
originally reported by Hedley et al (1983). Briefly the sections were
dewaxed in xylene, gradually rehydrated in a step series of ethanol
solutions, and digested using proteinase XXIV (Sigma-Aldrich,
Dorset, UK) 2.5mg for 2h at 371C. The sample was washed
in phosphate-buffered saline (PBS), filtered though 40mm nylon
mesh cell strainer (BD Biosciences, California, USA) and
resuspended in 1.5ml PBS. The nuclear suspension was then split
with 500ml for ICDA and 1000ml for FC.
A total of 100ml of nuclear suspension was pipetted into a
Shandon single use ez-cytofunnel (Thermo Scientific, Basingstoke,
UK) and spun onto Superfrost Plus (blue) microscope slide
(electrostatically permanently positive charge, VWR, Dorset, UK)
using a Shandon Cytospin 2 (at  225g for 5min) to form a
nuclear monolayer. The monolayer was dried for 1h and then
placed in 200ml HCl 5moll
–1 for 1h. The slide was then stained
with Feulgen–Schiff reagent using standardised methodology
(Bocking et al, 1995).
Measurement of DNA ploidy The Fairfield DNA Ploidy system
(Fairfield Imaging, Kent, UK) is an automated image cytometric
analyser that consists of a Zeiss Axioplan microscope (Zeiss,
Jena, Germany), a 546-nm green filter and a black-and-white,
high-resolution digital camera (model C4742-95, Hamamatsu
Photonics, Japan). Optical density and nuclear area were measured
and integrated optical density of each nucleus was calculated.
Background optical density was corrected for each nucleus.
Segmentation software (a range of pre-defined criteria relating to
the physical properties of the nuclei) automatically selects whole
nuclei. At least 1000 nuclei were scanned automatically and sorted
into four separate galleries for each cell type: nuclei of interest
for measurement, lymphocytes, plasma cells and fibroblasts. The
lymphocytes were used as reference cells to determine the position
of the diploid peak (2c). The galleries were then edited manually to
discard any cut or overlapping nuclei. The integrated optical
density of each nucleus of interest was calculated and a histogram
of DNA content produced. Ploidy-related parameters such as DNA
index (DI) and percentages of cells exceeding 5c (5c ER) and 9c
(9c ER) were also noted.
Histograms were analysed according to European Society for
Analytical Cellular Pathology guidelines (Bocking et al, 1995) as
follows:
(i) A specimen was defined as diploid when there was only one
peak (which was 2c, or DI¼0.9–1.1) during the G0 or G1
phase, when the number of 4c nuclei during the peak of the
G2 phase did not exceed 6% of the total, or when the number
of nuclei with a DNA content of 45c did not exceed 1% of the
total.
(ii) A specimen was defined as DNA tetraploid when there was
a population of 4C nuclei (DI¼1.9–2.1) 46% of the total,
representing stage G2 of the cell cycle. The term ‘DNA
tetraploid’ generally means a DNA content indistinguishable
from that of tetraploid cells, with a percentage of these cells
disproportionately higher than that of the S phase fraction.
(iii) A specimen was defined as aneuploid when there was a
population of nuclei with abnormal DNA content, separated
from the diploid peak (DI41.1), and representing 42.5% of
the total or when the number of nuclei with a DNA content of
45c or 9c exceeded 1% of the total. Aneuploid cases were
further divided into near-diploid aneuploid (1.1–1.29) and
aneuploid (1.30–1.89) (Lindahl et al, 1994).
All specimens were given unique coded identifiers and the
histograms were reported blindly by two of three independent
observers (JD, GM and MN). Consensus was reached in all cases.
Flow cytometry
Standard FC was performed according to a conventional protocol
and the manufacturer’s instruction. Briefly, after splitting of the
nuclear suspension, the 1000ml of supernatant was triturated with
a 26 gauge needle, resuspended in an isotonic pH 7.4-buffered
solution with 0.1% nonidet P-40 detergent, 10mgml
–1 diamidino-
2-phenylindole and 1% RNAse, and filtered through 40mm steel
mesh. The analysis was performed on a Cytopeia InFlux cytometer
using UV excitation. Chicken erythroid nuclei were used as
reference cells to determine the position of the diploid peak (2c).
A total of 50000 cells were analysed, if available, and in all cases,
acceptable histograms contained at least 10000 cells and a
coefficient of variation (CV) below 6.0%. The DNA content and
cell cycle were analysed as earlier described using the software
program MultiCycle (Phoenix Flow Systems, San Diego, CA, USA)
(Rabinovitch, 1994).
PDT patients
The criteria for inclusion were as follows:
(a) Confirmed HGD before treatment: At least two endoscopies
before PDT with large-capacity four-quadrant biopsies every
2cm of BE showing HGD. Histology was confirmed by two
experienced independent specialist GI pathologists. The EMR
was undertaken of any raised areas and only patients with
residual HGD after EMR were given PDT. DNA ploidy was
analysed on all four biopsies from each 2cm level of BE. All
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spatients had DNA ploidy analysis on HGD biopsies at one or
multiple levels from their enrolment endoscopy.
(b) Successful treatment with no dysplasia at follow-up: All
patients were treated with five aminolaevulinic acid (ALA)
PDT as described earlier (Mackenzie et al, 2007, 2009). Ethical
approval was granted for the study (EudraCT No: MF 8000
21074).
After PDT patients underwent endoscopy with four-quadrant
biopsies every 2cm from the treated oesophagus at 6 weeks, 4 and
12 months after PDT and at 18, 24, 36, 48 and 60 months. At each
follow-up, endoscopy after PDT care was taken to ensure that the
whole of the treated area was sampled, to ensure no buried glands
were missed in areas that had healed with squamous regeneration.
Assessment of DNA ploidy post-PDT was carried out on all
specimens with glandular epithelium, or mixed squamo-glandular
epithelium. Biopsies with squamous epithelium alone were not
analysed.
All patients treated with PDT who were free of residual disease
at 12 months were included in this prospective study. To be
considered disease free, patients must have had at least three
endoscopies over at least 12 months post-PDT. Relapse was
defined as presence of HGD or cancer during follow-up.
Statistical methods
All analysis was performed using either SPSS for Windows statistical
package (SPSS Inc., Version 14.0, Chicago, IL, USA) or Stata for
Windows (StataCorp LP, Version 10.1, College Station, TX, USA) The
two-tailed P-value of o0.05 was considered significant. The
differences between FC and IC of the CV, mean nuclei of G1 peak
and DI of aneuploid peak were analysed using paired t-tests.
Hazard ratios (HRs) for late relapse (HGD or cancer beyond
1 year) were estimated using the Cox proportional hazards model
and their significance was assessed using the log-rank test (for
categorical factors: sex, the presence of DNA ploidy abnormalities
before 4 and 12 months after treatment) or the Wald’s test (for
continuous variables: age and length of BE pre-PDT).
RESULTS
Comparison of FC vs ICDA
A total of 44 samples from 31 patients were successfully analysed,
and 93% (41 out of 44) were classified identically between the two
centres. All seven controls were diploid at both centres. Of the 34
cases for which there was agreement, 67% were aneuploid, 9%
tetraploid and 24% diploid. Coefficient of variation of the G1 peak
was lower by FC than ICDA (P¼0.04). Mean number of nuclei
collected was significantly lower by ICDA (520) than FC (12050)
(Po0.001). There was no significant difference in the DI of the
aneuploid peak between the two methods. A summary of the data
is presented in Appendix (Table A1).
Representative histograms are shown in Figure 1. Three cases
gave discordant results. One was reported as near-diploid
aneuploid by FC, but diploid by ICDA. The near-diploid peak at
DI¼1.16 diagnosed by FC (Figure 1B) is not found in image
cytometry galleries, although two small blips in the S phase that are
likely to be the G2 of each peak are apparent in both FC and ICDA
histograms. One explanation is that because of poor staining, the
real G1 peak was gated out by ICDA software, which is confounded
by the low nuclei number analysed (n¼236) when compared with
FC (n¼13942). This case shows the strength of FC, as analysis of
larger cell samples provides histograms with better resolution and,
therefore, aneuploid peaks in the near-diploid range are more
readily detected.
A second discordant case (not shown) had similar histograms
between the two centres, but a small aneuploid peak of 5.9% of the
total, seen at DI¼1.44 by FC, was not of sufficient magnitude to be
called aneuploid by ICDA.
The third discordant case (Figure 1C) was classified as DNA
tetraploid by ICDA, but diploid by FC (Figure 1C). There were low
nuclei numbers for both centres in this sample, though when
analysing the FC histogram, there is a high level of background
aggregates and debris, which overlies the 4N peak and complicates
its quantitation. ICDA allowed inspection of the events within this
peak and abnormal nuclei were shown within the image gallery at
the 4c region. This case shows an advantage of ICDA over FC, the
ability to directly visualise abnormal nuclei and make a diagnosis
of DNA ploidy abnormalities even if debris or aggregates overlap
with the 4c region.
ICDA post-PDT
A cohort of 30 patients who were treated with ALA PDT for HGD
arising in BE, and who remained clear of dysplasia for at least 12
months after treatment, were studied for factors predictive of
future relapse. In particular, DNA ploidy was assessed by ICDA on
all biopsies taken before treatment, and at 4 and 12 months post-
treatment. There were 13 cases of late relapse (7 cancer, 6 HGD)
and 17 patients who remained free of relapse for a mean of 44
months (including 12 months).
There were 1177 months of follow-up (from treatment) in the 30
patients (mean 39 months/patient, IQR 12–64 months) corre-
sponding to just over 68 years beyond 1-year post-treatment. The
annual rate of recurrence (including cancer beyond 1 year) was
19%. Median relapse-free interval was 3.6 years.
Patient characteristics and results of survival analysis are shown
in Table 1. None of age, sex or length of Barrett’s pre-PDT had a
significant effect on late relapse.
A total of 469 samples were processed for DNA ploidy from
these 30 patients. A summary of the raw data is presented in
Appendix (Tables A2 and A3). Representative histograms are
shown in Figures 2 and 3.
Before treatment, all but 5 of the 30 patients were aneuploid
and there was no significant difference in relapse rates with
aneuploidy. At 4 months after treatment, 10 patients were
aneuploid. Patients who were aneuploid at 4 months were
significantly more likely to have late relapse (HR¼4.1,
P¼0.009). At 12 months DNA ploidy was assessed in 29 patients:
10 were aneuploid and 2 had DNA tetraploidy, both also had
aneuploidy. Aneuploidy at 12 months was a significant predictor of
subsequent relapse (HR¼3.6, P¼0.03).
We then compared all 14 patients with DNA ploidy abnormal-
ities at 4 or 12 months with those with that were diploid.
This variable was extremely predictive of recurrence beyond 12
months: HR¼8.2 (1.8–37.8) log-rank P¼0.001 (Figure 4C).
It is noticeable that the survival curves begin to diverge earlier
for DNA ploidy at 4 months compared with DNA ploidy at
12 months (Figure 4A and B). We, therefore, also looked at DNA
ploidy as a time-dependent covariate, taking DNA ploidy at 4
months as the covariate value for recurrence between 12 and 20
months and DNA ploidy at 12 months (if available) to predict
recurrence beyond 20 months post-treatment. This time-depen-
dent covariate gave an HR of 6.3 (1.7–23.4), log-rank P¼0.0015.
None of the other variables recorded had a significant effect on
recurrence beyond 12 months.
DISCUSSION
These data show that ICDA is highly accurate for the diagnosis of
DNA ploidy abnormalities when compared with FC, the current
gold standard. These findings are strengthened by the blinded
study design, and comparison with a reference laboratory with a
wealth of experience in FC and BE. This experiment shows the
ICDA predicts relapse post-PDT
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spotential advantages of each technique. ICDA accurately quantifies
DNA tetraploidy, by permitting direct visualisation and selection
of cell populations that are in the 4c region. The importance of
DNA tetraploidy in BE has been earlier documented by the
Seattle group, with a tetraploid fraction above 6% associated with
an elevated risk of progression to cancer (Rabinovitch et al, 2001).
Moreover, it is unusual to find an elevated S phase fraction in
combination with a DNA tetraploid fraction above 6%, consistent
with the group’s published findings that elevated S phase fractions
are not statistically associated with risk of progression to cancer in
BE, whereas DNA tetraploid fractions are.
In contrast to ICDA, FC analysed significantly larger cell
samples and provided histograms with better resolution, so
aneuploid peaks in the near-diploid range were more readily
detected. The importance of near-diploid aneuploidy is unclear.
Earlier FC data from UW showed that 9% of the patients with
DI¼1.1–1.35 progressed to cancer, compared with 44% who had
DI 41.35 (Rabinovitch et al, 2001). Importantly, in that study, no
patient with a near-diploid DNA content progressed to cancer
within 5 years of their baseline endoscopy.
The comparison of the two techniques has been evaluated
in many tumours with concordance rates of 70–94% in breast
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Figure 1 Histograms by FC and ICDA (left to right). (A) Aneuploid case by FC and ICDA. (B) Discordant case, near-diploid aneuploid by FC
and diploid by ICDA. Note that both analysis methods show evidence of separate G2 peaks. (C) Discordant case, diploid by FC and tetraploid
by ICDA.
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scancer (Lee et al, 1991; Baldetorp et al, 1992; Chen et al, 1995) and
81–100% in gynaecological tumours (Kaern et al, 1992; Esposito
and Fuchs, 1994). In BE, the published data comparing the
two techniques are limited to a single study by Goyal et al on
27 patients, that is 10 normal controls and 17 with Barrett’s
adenocarcinoma (Huang et al, 2008). Image cytometry was carried
out on thin sections of FFPE tissue and areas of interest marked
before scanning using Automated Cellular Imaging System. This
method is potentially advantageous as mixed squamo-glandular
epithelium, which may variably dilute the glandular epithelium of
interest, is not included. The authors concluded that IC detected
aneuploidy in all adenocarcinoma samples, whereas FC missed the
diagnosis of aneuploidy in 29%. There were, however, limitations
to this study. IC and FC were carried out in the same laboratory
with no independent review of histograms, and there was no
validation of FC technique. The two techniques were carried out on
different cut samples (7mm IC, 2  50mm FC), thereby making it
difficult to draw a direct comparison. Finally, no patients were
reported as DNA tetraploidy, an important independent marker of
disease progression. This may be explained by the study design, as
only cancers were analysed for DNA ploidy, and DNA tetraploidy
can appear early in the cascade of genetic change. This may also be
explained by introduction of a cutting error of the larger tetraploid
nuclei when using 7mm sections, leading to underestimation of
tetraploid fraction.
We have gone on to show the value of DNA ploidy measured by
ICDA as a biomarker to predict late relapse to HGD and cancer
in BE, after successful treatment of dysplasia by PDT. DNA
ploidy abnormalities after treatment conferred an HR of 8.2
(1.8–37.8) for developing recurrent HGD or cancer. Rabinovitch
et al (2001) earlier showed that aneuploidy arising in non-
dysplastic BE, as measured by FC, conferred a relative risk for
progression to cancer of 4.4 (CI¼1.4–14). These earlier data are
consistent with the findings of our study.
The importance of residual genetic abnormalities in Barrett’s
epithelium after PDT has earlier been postulated. Foultier et al
(1994) assessed the influence of DNA ploidy abnormalities
on outcomes in patients with early gastrointestinal cancer
(oesophageal, gastric, colorectal) treated by haematoporphyrin
derivative PDT. Aneuploidy (measured by FC) at 4-month follow-
up was associated with a poor response, with only 5 of 15 patients
with aneuploidy achieving complete remission, compared with
12 of 17 patients without aneuploidy. Prasad et al (2008) reported
on the correlation of histology with biomarker status after
photofrin PDT, in which overall fluorescence in situ hybridisation
positivity for a panel of biomarkers (including loss of p16 and
Table 1 Patient characteristics and survival analysis
Mean IQR HR 95%CI P-value
Male 83% 0.47 0.12–1.78 0.25
Age (years) 69 60–77 1.01 0.96–1.07 0.62
Barrett’s length before PDT (cm) 5.7 4–7 1.07 0.88–1.30 0.51
Aneuploidy pre-PDT 83% 0.75 0.20–2.79 0.66
Aneuploidy 4months post-PDT 33% 4.1 1.3–13.0 0.009
Aneuploidy 12months post-PDT
(n¼29)
34% 3.6 1.05–12.3 0.029
Aneuploidy 4 and/or 12months
post-PDT
47% 8.2 1.8–37.8 0.0012
Abbreviations: CI¼confidence interval; HR¼hazard ratio; PDT¼photodynamic
therapy.
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Figure 2 Histograms from a patient who relapsed to cancer at 24 months. (A) Aneuploid histogram before PDT with DI¼1.7. (B) Persistent aneuploidy
post-PDT with DI¼1.7.
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Figure 3 Histograms from a patient who was disease free at 42 months. (A) Aneuploid histogram before PDT with DI¼1.8. (B) Diploid 4 months
post-PDT.
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sp53) was seen in 60% of non-responders to sp-PDT vs 19% of
responders. No individual biomarker, however, was shown to
predict success or failure of therapy.
DNA ploidy changes before and after PDT suggest that ALA acts
directly on cancer cells in addition to vascular effects leading to
oxygen deprivation and apoptosis (Foultier et al, 1994). A total of
13 out of 30 patients did not achieve reversal of DNA ploidy
abnormalities despite normal histology, which suggests that
dysplastic cell populations in BE do not act in the same way to
treatment. One postulated theory on the histogenesis of BE is that
heterogeneity arises from multiple independent clones, in contrast
to the selective sweep to fixation model of clonal expansion
described earlier (Leedham et al, 2008). This may explain why
sub-populations of cells may occur that are resistant to therapy
and continue to display genetic abnormalities.
The occurrence of diploid cell populations in HGD tissue was
noted in five patients before treatment. A total of 3 out of
5 patients have relapsed, with 2 out of 3 cases showing no
DNA ploidy abnormalities in the first year. Further analysis of
DNA ploidy was undertaken on all biopsies taken from these
patients after 1 year, and both showed DNA ploidy abnormalities
before developing cancer. In the first, aneuploidy was found at
2 years post-PDT, 6 months before cancer was diagnosed. In the
second, DNA tetraploidy was found 18 months post-PDT. Cancer
developed 3 years later. This may be explained by sampling error,
as small aneuploid populations may be missed by ICDA. Another
argument would be ALA PDT induced mutation and up-regulation
of an aneuploid clone not earlier quantified. This has been shown
in studies on glioblastoma cell lines in which ALA can lead to up-
regulation of putative cancer stem cells that are resistant to therapy
(Morgan and Petrucci, 2009).
There are some limitations to this study. Despite significant
differences between groups, the sample size is small. Kaplan–
Meier plots and survival analysis methods allow for whatever
follow-up time is available for each person, thereby maximising
our sample size and allowing statistically significant conclusions
to be drawn. The significance of endoscopic sampling error is
difficult to quantify. It is possible that small foci of dysplasia
may be missed at follow-up endoscopy using current standard
four-quadrant surveillance. However, after three clear endoscopies,
we estimate this miss rate to be small.
DNA ploidy measured by ICDA is accurate when compared with
FC, with advantages of cost effectiveness, potential for automation and
routine analysis of paraffin-embedded tissue. It is important to note
that both ICDA and FC examine predominately whole nuclei, and it is
less likely that these findings would be replicated by analysis of cut
nuclei from thin sections. Furthermore, DNA ploidy abnormalities by
ICDA predict risk of relapse after ablative therapy, and may be
clinically useful as a biomarker by allowing an individualised approach
to patient follow-up. If stratifying risk according to DNA ploidy status
after ablative therapy, then patients with residual aneuploidy would
require intensive surveillance, whereas diploid patients may return to
3 yearly surveillance and be reassured of a very low cancer risk. The
reduction in the frequency of follow-up endoscopies for the majority
of patients would also provide financial savings for healthcare services.
The study is limited by its retrospective design and a larger
prospective study using reversal of DNA ploidy abnormalities as an
end point for treatment success would be valuable.
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Figure 4 Kaplan–Meier disease-free survival estimates according to
DNA ploidy status at (A) 4 months, (B) 1 year and (C) at both time points
post-ALA PDT. Blue¼diploid post-PDT, red¼DNA ploidy abnormalities
post-PDT (The colour reproduction of this figure is available on the html
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Raw data
Table A1 Comparison of flow cytometry vs image cytometric DNA analysis (ICDA)
Specimen
ID Histology
DNA ploidy
ICDA
Nuclei
in G1
peak CV
Peak
DNA
index DNA ploidy flow cytometry
Nuclei in
G1 peak CV
Peak
DNA
index
1 Intramucosal
adenocarcinoma
Aneuploid 1864 6.45 1.36 1 aneuploid cycle 14339 5.22 1.34
3 HGD Aneuploid
(near diploid)
851 4.02 1.17 Aneuploid (bimodal) 10987 7.58 1.19
4 Intramucosal
adenocarcinoma
Aneuploid 360 11.50 1.56 1 aneuploid cycle 11769 9.17 1.58
5 HGD Aneuploid 1406 6.30 1.43 1 aneuploid cycle 11816 5.74 1.36
6 HGD Diploid 222 5.82 Diploid (with shoulder, high debris) 9025 7.45
7 Intramucosal
adenocarcinoma
Aneuploid 366 5.35 1.85 2 interpretations: 1 aneuploid cycle;
aneuploid cycle+bimodal aneuploid
10901 6.7 1.64
8 HGD Aneuploid and
tetraploid
1777 8.44 1.52 and
2.05
Aneuploid cycle+elevated 4N 11160 7.28 1.41
10 HGD Tetraploid 248 9.07 Diploid (high debris) 10015 9.71
11 CIS Aneuploid 1042 4.66 5CER
3.36%
1 aneuploid cycle (high DI) 11743 4.1 3.02
12 HGD Diploid 460 5.77 Diploid 13397 4.47
13 CIS Probable
diploid
133 13.20 Diploid 10358 9.84
15 CIS Probable
diploid
166 10.36 Borderline quality, probably diploid 5559 8.49
16 HGD Aneuploid 269 6.35 1.44 1 aneuploid cycle 9687 6.06 1.41
17 Squamous Diploid 606 6.46 Diploid 13667 4.94
18 Adenocarcinoma Aneuploid 529 7.82 1.28 1 aneuploid cycle 10952 3.83 1.25
19 Squamous Diploid 1010 5.20 Diploid 10981 4.67
20 Adenocarcinoma Diploid 329 5.01 Diploid (shoulder present but too
small to call, and not quite bimodal)
11390 5.15
21 Squamous Diploid 848 4.90 Diploid 12195 5.33
22 Adenocarcinoma Diploid 241 4.48 1 aneuploid cycle 14003 4.81 1.44
23 Squamous Diploid 167 13.29 Diploid 10284 4.47
24 Adenocarcinoma Aneuploid  2 299 6.09 1.34+1.51 2 aneuploid cycles 11503 4.8 1.31+1.51
25 Squamous Diploid 205 7.44 Diploid 10678 6.41
26 Adenocarcinoma Aneuploid  2 798 5.30 DI
1.44+5CER
2 aneuploid cycles 9917 7.88 1.36
27 Squamous Diploid 269 5.78 Diploid 13263 6.81
28 Adenocarcinoma Diploid 236 4.98 1 aneuploid cycle 13942 4.48 1.16
29 Barrett’s IM Diploid 264 4.69 Diploid 14439 4.94
30 IMC Aneuploid 609 6.75 1.53 1 aneuploid cycle 15413 5.85 1.51
31 Adenocarcinoma Aneuploid  2 204 9.58 1.76 and
2.20
2 aneuploid cycles, diploid G2 DI is
high. Alternatively, could be third
aneuploid
12560 5.83 1.48+1.78
32 Adenocarcinoma Diploid 350 7.92 Diploid 12858 4.78
33 Adenocarcinoma Diploid 1350 7.04 Diploid 11952 4.91
34 Adenocarcinoma Aneuploid 279 6.20 1.61 1 aneuploid cycle (aneuploid may
be bimodal)
13693 5.91 1.60
35 Adenocarcinoma Tetraploid 268 6.60 Elevated 4N 14634 4.64
36 Adenocarcinoma Aneuploid 486 9.55 1.79 1 aneuploid cycle 13263 6.01 1.73
37 Adenocarcinoma Aneuploid  2 327 3.95 1.52+5CER 2 aneuploid cycles 13987 4.54 1.20+1.42
38 Adenocarcinoma Aneuploid 383 4.85 1.31 1 aneuploid cycle 15839 4.54 1.53
39 Adenocarcinoma Aneuploid 230 3.84 1.59 1 aneuploid cycle 14572 4.05 1.56
40 Adenocarcinoma Tetraploid 508 6.68 Elevated 4N 11258 4.47
41 Adenocarcinoma Aneuploid 228 4.18 5CER 1 aneuploid cycle (tiny) 16392 4.17 1.77
42 Adenocarcinoma Aneuploid 777 6.37 1.73 1 aneuploid cycle 14100 5.37 1.74
43 Adenocarcinoma Aneuploid  2 413 5.37 1.40+2.53 2 interpretations: 1 aneuploid cycle;
2 aneuploid cycles
11720 6.98 1.41
44 Adenocarcinoma Aneuploid and
tetraploid
650 15.34 1.44 1 aneuploid cycle, elevated 4N 8624 5.12 1.27
45 Adenocarcinoma Aneuploid 216 6.98 1.52+1.9 2 aneuploid cycles 7531 4.83 1.47+1.72
46 Adenocarcinoma Diploid 310 10.54 Diploid 13872 10.64
48 Adenocarcinoma Aneuploid 348 7.56 1.67 1 aneuploid cycle 10116 5.68 1.58
Abbreviations: CV¼coefficient of variance; DI¼DNA index; HGD¼high-grade dysplasia; ICDA¼image cytometric DNA analysis. Cases 1–16¼EMR specimens;
17–48¼oesophagectomy specimens. Discordant cases are highlighted in gray.
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